Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Prestige Biopharma and Pharmapark Announce License and Supply Agreement to Commercialize Prestige's Trastuzumab Biosimilar in the Russian Federation

b3cnewswireJuly 08, 2019

Tag: Trastuzumab biosimilar , Prestige BioPharma , Pharmapark

PharmaSources Customer Service